Pilot Study Using Propranolol To Promote Prenylation Of The Gtpase Rap1b In Hematopoietic Stem Cell Transplant Recipients
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Blood Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 3/30/2019 |
| Start Date: | August 2015 |
| End Date: | August 2019 |
This is a an ancillary study designed to explore whether an additional cell signaling pathway
(prenylation of Rap1) that was recently identified as being under beta-adrenergic control may
be affected by beta-blocker use.
(prenylation of Rap1) that was recently identified as being under beta-adrenergic control may
be affected by beta-blocker use.
This is a proof of concept randomized controlled pilot study assessing whether prenylation
and membrane localization of Rap1 in PBMCs can be altered in individuals undergoing
autologous HCT for MM by administering a daily beta-blocker (propranolol) to 20 participants.
Outcomes of patients on this clinical trial will be compared to 20 participants in a control
arm.
and membrane localization of Rap1 in PBMCs can be altered in individuals undergoing
autologous HCT for MM by administering a daily beta-blocker (propranolol) to 20 participants.
Outcomes of patients on this clinical trial will be compared to 20 participants in a control
arm.
Patients who are eligible for enrollment in the parent study.
We found this trial at
1
site
Click here to add this to my saved trials
